Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
Completed · Phase 3 · NCT04684524
Conditions: Allergic Fungal Rhinosinusitis
At a glance
- Research payments reported, 2025
- $50,756
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (drug), Placebo (drug)
- Dates
- Started 2020-12-01; completion 2025-03-07
- Results posted
- Yes
Primary Objective: * To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: * To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) at Week 24 * To assess the efficacy of dupilumab to reduce the need for rescue treatments * To evaluate the efficacy of treatment with dupilumab in improving symptoms in AFRS * To evaluate the efficacy of dupilumab to reduce nasal polyp formation in participants with AFRS * To evaluate the efficacy of dupilumab in improving overall symptom severity and quality of li…
From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $50,756 in research payments for this study in 2025 (13 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Justin H. Turner, M.D., PH.D. ENT (Otolaryngology) · Birmingham, AL
- Steven C. Choung, M.D. Orthopedic Surgery · Orlando, FL
- Joshua M. Levy, DMD, MD Oral & Maxillofacial Surgeons · Marietta, GA
- James L. Connolly, M.D. Facial Plastic Surgery · Mandeville, LA
- Jeffery S. Rosenbloom, MD ENT (Otolaryngology) · San Antonio, TX
- Joseph K. Han, MD ENT (Otolaryngology) · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Vanderbilt University Medical Center, TN $30,247
- University of South Florida $7,000
- Eastern Virginia Medical School Department of Internal Medicine $4,508
- Emory University Hospital, GA $4,300
- $2,500
- Alamo Ent Associates $1,200
- Biopharma Clinical Research Services Llc $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.